Combating Pancreatic Cancer with PI3K Pathway Inhibitors in the Era of Personalised Medicine

Overview

Journal Gut

Specialty Gastroenterology

Date 2018 Nov 7

PMID 30396902

Citations 49

Authors

James Rw Conway

David Herrmann

Tr Jeffry Evans

Jennifer P Morton

Paul Timpson

Affiliations

Soon will be listed here.

Abstract

Pancreatic ductal adenocarcinoma (PDAC) is among the most deadly solid tumours. This is due to a generally late-stage diagnosis of a primarily treatment-refractory disease. Several large-scale sequencing and mass spectrometry approaches have identified key drivers of this disease and in doing so highlighted the vast heterogeneity of lower frequency mutations that make clinical trials of targeted agents in unselected patients increasingly futile. There is a clear need for improved biomarkers to guide effective targeted therapies, with biomarker-driven clinical trials for personalised medicine becoming increasingly common in several cancers. Interestingly, many of the aberrant signalling pathways in PDAC rely on downstream signal transduction through the mitogen-activated protein kinase and phosphoinositide 3-kinase (PI3K) pathways, which has led to the development of several approaches to target these key regulators, primarily as combination therapies. The following review discusses the trend of PDAC therapy towards molecular subtyping for biomarker-driven personalised therapies, highlighting the key pathways under investigation and their relationship to the PI3K pathway.

Citing Articles

Targeting the NPY/NPY1R signaling axis in mutant p53-dependent pancreatic cancer impairs metastasis.

Chambers C, Watakul S, Schofield P, Howell A, Zhu J, Tran A Sci Adv. 2025; 11(11):eadq4416.

PMID: 40073121 PMC: 11900870. DOI: 10.1126/sciadv.adq4416.

WWP1 inhibition suppresses the proliferation of pancreatic cancer cells by regulating the PI3K-AKT pathway.

Notoya G, Kishikawa T, Yasugi K, Iwata T, Seimiya T, Miyabayashi K J Gastroenterol. 2024; 60(3):370-384.

PMID: 39656237 PMC: 11880106. DOI: 10.1007/s00535-024-02192-x.

Inhibition of the PI3K/AKT/mTOR pathway in pancreatic cancer: is it a worthwhile endeavor?.

Ouissam A, Hind C, Sami Aziz B, Said A Ther Adv Med Oncol. 2024; 16:17588359241284911.

PMID: 39399412 PMC: 11468005. DOI: 10.1177/17588359241284911.

Sulindac (K-80003) with nab-paclitaxel and gemcitabine overcomes drug-resistant pancreatic cancer.

Xie C, Liao C, Lin H, Wu Y, Lu F, Huang X Mol Cancer. 2024; 23(1):215.

PMID: 39350121 PMC: 11441089. DOI: 10.1186/s12943-024-02128-2.

Emerging Trends in Gastrointestinal Cancer Targeted Therapies: Harnessing Tumor Microenvironment, Immune Factors, and Metabolomics Insights.

Rauth S, Malafa M, Ponnusamy M, Batra S Gastroenterology. 2024; 167(5):867-884.

PMID: 38759843 PMC: 11793124. DOI: 10.1053/j.gastro.2024.05.005.

References

. Cancer risks in BRCA2 mutation carriers. J Natl Cancer Inst. 1999; 91(15):1310-6. DOI: 10.1093/jnci/91.15.1310. View

Greenlee R, Murray T, Bolden S, Wingo P . Cancer statistics, 2000. CA Cancer J Clin. 2000; 50(1):7-33. DOI: 10.3322/canjclin.50.1.7. View

Goggins M, Hruban R, Kern S . BRCA2 is inactivated late in the development of pancreatic intraepithelial neoplasia: evidence and implications. Am J Pathol. 2000; 156(5):1767-71. PMC: 1876938. DOI: 10.1016/S0002-9440(10)65047-X. View

Heinmoller E, Dietmaier W, Zirngibl H, Heinmoller P, Scaringe W, Jauch K . Molecular analysis of microdissected tumors and preneoplastic intraductal lesions in pancreatic carcinoma. Am J Pathol. 2000; 157(1):83-92. PMC: 1850206. DOI: 10.1016/S0002-9440(10)64520-8. View

Hruban R, Goggins M, Parsons J, Kern S . Progression model for pancreatic cancer. Clin Cancer Res. 2000; 6(8):2969-72. View

Safran H, Steinhoff M, Mangray S, Rathore R, King T, Chai L . Overexpression of the HER-2/neu oncogene in pancreatic adenocarcinoma. Am J Clin Oncol. 2001; 24(5):496-9. DOI: 10.1097/00000421-200110000-00016. View

Zhou B, Liao Y, Xia W, Zou Y, Spohn B, Hung M . HER-2/neu induces p53 ubiquitination via Akt-mediated MDM2 phosphorylation. Nat Cell Biol. 2001; 3(11):973-82. DOI: 10.1038/ncb1101-973. View

Mayo L, Dixon J, Durden D, Tonks N, Donner D . PTEN protects p53 from Mdm2 and sensitizes cancer cells to chemotherapy. J Biol Chem. 2001; 277(7):5484-9. DOI: 10.1074/jbc.M108302200. View

Cartwright T, Cohn A, Varkey J, Chen Y, Szatrowski T, Cox J . Phase II study of oral capecitabine in patients with advanced or metastatic pancreatic cancer. J Clin Oncol. 2002; 20(1):160-4. DOI: 10.1200/JCO.2002.20.1.160. View

10.

Gottlieb T, Martinez Leal J, Seger R, Taya Y, Oren M . Cross-talk between Akt, p53 and Mdm2: possible implications for the regulation of apoptosis. Oncogene. 2002; 21(8):1299-303. DOI: 10.1038/sj.onc.1205181. View

11.

Klein W, Hruban R, Klein-Szanto A, Wilentz R . Direct correlation between proliferative activity and dysplasia in pancreatic intraepithelial neoplasia (PanIN): additional evidence for a recently proposed model of progression. Mod Pathol. 2002; 15(4):441-7. DOI: 10.1038/modpathol.3880544. View

12.

Kleeff J, Fukahi K, Lopez M, Friess H, Buchler M, Sosnowski B . Targeting of suicide gene delivery in pancreatic cancer cells via FGF receptors. Cancer Gene Ther. 2002; 9(6):522-32. DOI: 10.1038/sj.cgt.7700464. View

13.

Van Heek N, Meeker A, Kern S, Yeo C, Lillemoe K, Cameron J . Telomere shortening is nearly universal in pancreatic intraepithelial neoplasia. Am J Pathol. 2002; 161(5):1541-7. PMC: 1850788. DOI: 10.1016/S0002-9440(10)64432-X. View

14.

Bardeesy N, DePinho R . Pancreatic cancer biology and genetics. Nat Rev Cancer. 2002; 2(12):897-909. DOI: 10.1038/nrc949. View

15.

Arboleda M, Lyons J, Kabbinavar F, Bray M, Snow B, Ayala R . Overexpression of AKT2/protein kinase Bbeta leads to up-regulation of beta1 integrins, increased invasion, and metastasis of human breast and ovarian cancer cells. Cancer Res. 2003; 63(1):196-206. View

16.

Freeman D, Li A, Wei G, Li H, Kertesz N, Lesche R . PTEN tumor suppressor regulates p53 protein levels and activity through phosphatase-dependent and -independent mechanisms. Cancer Cell. 2003; 3(2):117-30. DOI: 10.1016/s1535-6108(03)00021-7. View

17.

Iacobuzio-Donahue C, Maitra A, Olsen M, Lowe A, Van Heek N, Rosty C . Exploration of global gene expression patterns in pancreatic adenocarcinoma using cDNA microarrays. Am J Pathol. 2003; 162(4):1151-62. PMC: 1851213. DOI: 10.1016/S0002-9440(10)63911-9. View

18.

Korc M, Chandrasekar B, Yamanaka Y, Friess H, Buchier M, Beger H . Overexpression of the epidermal growth factor receptor in human pancreatic cancer is associated with concomitant increases in the levels of epidermal growth factor and transforming growth factor alpha. J Clin Invest. 1992; 90(4):1352-60. PMC: 443180. DOI: 10.1172/JCI116001. View

19.

Schlieman M, Fahy B, Ramsamooj R, Beckett L, Bold R . Incidence, mechanism and prognostic value of activated AKT in pancreas cancer. Br J Cancer. 2003; 89(11):2110-5. PMC: 2376856. DOI: 10.1038/sj.bjc.6601396. View

20.

Neoptolemos J, Stocken D, Friess H, Bassi C, Dunn J, Hickey H . A randomized trial of chemoradiotherapy and chemotherapy after resection of pancreatic cancer. N Engl J Med. 2004; 350(12):1200-10. DOI: 10.1056/NEJMoa032295. View